|
Fibrinolysis
Citations 111-120 of 146 total displayed.
|
Past content
(since Jan 1999):
|
- Clinical Investigations and Reports
Time to Treatment Influences the Impact of ST-Segment Resolution on One-Year Prognosis: Insights From the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Trial
- Yuling Fu, Shaun Goodman, Wei-Ching Chang, Frans Van de Werf, Christopher B. Granger, and Paul W. Armstrong
Circulation 2001;104:2653-2659, doi:10.1161/hc4701.099731
[Abstract]
[Full text]
- Thoracic Transplantation and Ventricular Assist Devices
Aprotinin But Not  -Aminocaproic Acid Decreases Interleukin-10 After Cardiac Surgery With Extracorporeal Circulation: Randomized, Double-Blind, Placebo-Controlled Study in Patients Receiving Aprotinin and -Aminocaproic Acid
- Philip E. Greilich, Kuniyuki Okada, Paige Latham, Ramaswamy Ravi Kumar, and Michael E. Jessen
Circulation 2001;104:I-265-269I-, doi:10.1161/hc37t1.094781
[Abstract]
[Full text]
- Clinical Investigations and Reports
Early Reinfarction After Fibrinolysis: Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials
- Michael P. Hudson, Christopher B. Granger, Eric J. Topol, Karen S. Pieper, Paul W. Armstrong, Gabriel I. Barbash, Alan D. Guerci, Alec Vahanian, Robert M. Califf, and E. Magnus Ohman
Circulation 2001;104:1229-1235, doi:10.1161/hc3601.095717
[Abstract]
[Full text]
- Correspondence
Death Rates Versus Deaths
- Kenneth M. Kessler, David A. Morrow, Elliott M. Antman, James A. de Lemos, Robert P. Giugliano, Carolyn H. McCabe, Eugene Braunwald, Sabina A. Murphy, Andrew Charlesworth, and Richard Cairns
Circulation 2001;104:e8
[Full text]
- Basic Science Reports
Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice
- Yanhong Zhu, Peter M. Farrehi, and William P. Fay
Circulation 2001;103:3105-3110
[Abstract]
[Full text]
- Cardiovascular Drugs
Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 2
- Paul W. Armstrong and Désiré Collen
Circulation 2001;103:2987-2992
[Full text]
- Cardiovascular Drugs
Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 1
- Paul W. Armstrong and Désiré Collen
Circulation 2001;103:2862-2866
[Full text]
- Clinical Investigations and Reports
Impaired Coronary Tissue Plasminogen Activator Release Is Associated With Coronary Atherosclerosis and Cigarette Smoking : Direct Link Between Endothelial Dysfunction and Atherothrombosis
- David E. Newby, Andrew L. McLeod, Neal G. Uren, Laura Flint, Christopher A. Ludlam, David J. Webb, Keith A. A. Fox, and Nicholas A. Boon
Circulation 2001;103:1936-1941
[Abstract]
[Full text]
- Correspondence
Plasminogen Activator Inhibitor Genotype and Brain Infarction • Response
- Alexis Elbaz, François Cambien, Pierre Amarenco, Mark Roest, Yvonne T. van der Schouw, Diederick E. Grobbee, Mariëlle J. Tempelman, Philip G. de Groot, Jan J. Sixma, and Jan Dirk Banga
Circulation 2001;103:e13-14e
[Full text]
- Correspondence
High Antifibrinolytic Activity of Lipoprotein(a) Containing Small Apolipoprotein(a) Isoforms • Response
- E. Anglés-Cano, Santica M. Marcovina, and Marlys L. Koschinsky
Circulation 2000;102:e184-185e
[Full text]
|
|
